The Juvenile Diabetes Cure Alliance (JDCA) celebrates its fifth year of service to the type 1 diabetes donor community. The JDCA was founded in 2011 by Brian G. Kelly, chairman of the board of Activision Blizzard, several years after his son was diagnosed with the disease.
The JDCA has consistently advocated for a significant increase in funding for type 1 diabetes cure research, and has evolved to become a trusted and independent source of fact-based analysis. JDCA publications are followed by over 75,000 people and the organization has directly influenced over $25 million of donations for type 1 diabetes.
“We are proud of the impact the JDCA has made in focusing attention on the critical need to increase cure research funding.”
With the purpose of accelerating speed to a cure, the JDCA challenges nonprofits to adopt many of the best practices of for-profit companies, such as transparency, performance-based compensation, accountability to donors, and focused strategic planning. Many of these managerial approaches are perceived as unorthodox among nonprofit organizations, and the JDCA is unique in its advocacy for these practices.
Donor Priorities and Money Use Not Aligned: An Ongoing Call to Action
Ninety percent of donors, when surveyed, stated that their number-one priority is to support cure research. Yet only 7 cents of every dollar given to type 1 diabetes fundraising organizations was used for cure research, and this amount has been declining for a decade. Unless this trend is reversed, it is unlikely a cure will be found in the foreseeable future.
“I believe that the JDCA is doing a very effective job of raising awareness within the philanthropic community of the need for organizations who receive charitable contributions to articulate a clear strategy for finding of a cure for type 1 diabetes and for them to explain how their donors’ dollars are being deployed accordingly,” says Geoff Rehnert, co-founder and CEO of Audax Group, and a founding member of Bain Capital.
During the fall of 2015, the JDCA launched the first annual petition aimed at restoring funding for type 1 diabetes cure research, which gained over 21,000 signatures. The second annual campaign will be launched in the summer of 2016.
“We are proud of the impact the JDCA has made in focusing attention on the critical need to increase cure research funding,” says Phil Shaw, General Manager of the JDCA. “Executives of the main T1D organizations follow our publications closely but there is still a long road ahead and we will stay at it until a cure is available for everyone who needs it.”